FTFarshid Taghizadeh

Farshid Taghizadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farshid Taghizadeh has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Palatal Island Flap for the Reconstruction of Oral and Oropharyngeal Defects

    by Farshid Taghizadeh, Allison A. Slijepcevic, Madison E. Colcord, Jonathon Chodroff, Mark K. Wax

    The palatal island rotation flap is a rarely used reconstructive technique. The tissue is robust and the morbidity is low. It can be used as a primary reconstructive technique in patients with limited oral cavity/pharynx lesions. Healing is uneventful. In radiated pateints healing is prolonged and should be avoided. We describe 14 patients where the flap was used to reconstruct local defects. Patients with no history of radiation all healed quickly and well. Those with a history of radiatiuon had prolonged pain and delayed healing. Laryngoscope , 134:2718–2720, 2024


  • Outcomes of Cranioplasty Reconstructions: Review of Cranioplasty Implants and Free Flap Coverage Variables that Affect Implant Exposure

    by Allison A Slijepcevic, Brian Scott, Gabriela L Lilly, Gavin Young, Farshid Taghizadeh, Ryan Li, Daniel Petrisor, Patrik Pipkorn, Jason Rich, Ryan Jackson, et al.

    Background: Complex scalp wounds with cranial/dural involvement are challenging to reconstruct. Successful reconstruction can be achieved with cranial implants/hardware and free flap coverage. Wounds can breakdown and require revision procedures. We addressed reconstructive outcomes of different implants requiring free flaps.Objective: To determine the factors associated with implant exposure.Design: Multi‐institutional retrospective review of 82 patients, 2000–2020, repaired with cranial implants and free flap coverage.Results: Implant exposure occurred in 13/82 (16%) reconstructions. Flap atrophy or thinning leading to implant exposure occurred in 11/82 (13%) reconstructions, including partial flap atrophy OR 0.05 (95% CI 0.0–0.35) and total flap atrophy OR 0.34 (95% CI 0.02–19.66). Revision surgeries that occurred subsequent to flap reconstruction were also associated with implant exposure (OR 0.02 (95% CI 0.0–0.19)). Implant exposure was not associated with radiation therapy, patient health history, implant type, flap type, or postoperative complications.Conclusions: Implant exposure is associated with free flap atrophy, leading to inadequate implant coverage and the need for revision surgeries. Completing reconstruction with adequate soft tissue bulk and coverage and avoiding revision surgery may decrease the risk for implant exposure over time.Level of Evidence: 4 Laryngoscope, 133:2954–2958, 2023


  • The Role of Fluorescent Angiography in Free Flap Reconstruction of the Head and Neck

    by Farshid Taghizadeh, Scott H. Troob, Mark K. Wax

    Objectives: Highlight the use of fluorescent angiography in free flap reconstruction of the head and neck. Qualify how fluorescent angiography can be selectively added to management paradigms for head and neck free flap reconstruction.Methods: Retrospective chart review of 993 free flaps completed from the time the SPY Elite® system first became available at our institution between September 2013, until August 2020. Cases that used the SPY Elite® system were grouped into three broad categories: evaluation during initial flap harvest while still attached to the donor site, evaluation after anastomosis in the head and neck area, and evaluation post‐operatively for questionable flap viability.Results: The SPY Elite® system was used in 64 cases. Forty flaps were evaluated intraoperatively during initial harvest and before anastomosis to the head and neck area. Of these, 20 had signs of poor perfusion of the entire skin paddle, 12 had large myogenous or skin flaps with questionable perfusion of the distal aspect, and 8 were evaluated for other reasons. In this group the use of SPY Elite® changed the management of the patient in 20 cases (50%). Ten flaps were evaluated intraoperatively after anastomosis to the head and neck to ascertain adequate flow to the entire flap. In this group management was changed in two (20%). Fourteen flaps were evaluated 3–5 days post operatively due to suspected failure of a component. In five cases (36%), the use of SPY Elite® determined management with either trimming or discarding the flap.Conclusion: Assessment of flap perfusion via fluorescent angiography during initial flap harvest or when flap compromise is suspected post‐operatively can guide decision making in free flap reconstruction of the head and neck and can be added to existing planning and management paradigms.Level of Evidence: 4 Laryngoscope, 133:1388–1393, 2023


  • Age and Comorbidities Impact Medical Complications and Mortality Following Free Flap Reconstruction

    by Larissa Sweeny, Joseph M. Curry, Meghan B. Crawley, Michael DiLeo, Caroline A. Bonaventure Bs, Adam J. Luginbuhl, Kelsie M. Guice, Farshid Taghizadeh, Eleanor McCreary, Michelle Buncke Ba, et al.

    Objective: Determine if age correlated with surgical or medical complications following head and neck free flap reconstruction.Study Design: Retrospective review of prospectively collected databases.Methods: Patients undergoing head and neck free flap reconstruction at three tertiary care institutions were included (n = 1972). Cohorts were based on age (85). Outcomes reviewed operative duration, length of stay, surgical complications (free flap failure, fistula, hematoma, dehiscence, and infection), and medical complications (thromboembolism, stroke, cardiac, and pulmonary).Results: Anatomic site (P < .0001) and donor site varied by age (P < .0001). There was no difference in operative duration (P = .3) or length of hospitalization (P = .8) by age. The incidence of medical complications increased with increasing age. Pulmonary complication rates: 85 (11%) (P = .02). Cardiac complication rates: 85 (16.4%) (P < .0001). Mortality increased with age: 85 (4.1%) (P < .003). Medical complications correlated with mortality rates: pulmonary (3.5% vs. 0.6%; OR: 5.5; 95% CI: 1.5–20.0; P = .004); cardiac (3.3% vs. 0.6%; OR: 6.0; 95% CI: 1.6–21.8; P = .002); thromboembolism (4.6% vs. 0.7%; OR: 7.3; 95% CI: 1.6–33.6; P = .003); stroke (42% vs. 0.5%; OR: 149; 95% CI: 40–558; P < .0001); and sepsis (5% vs. 0.7%; OR 7.5; 95% CI: 1.0–60.5; P = .03). Age did not correlate with free flap success (P = .5), surgical complications (hematoma, P = .33; fistula, P = .23; infection, P = .07; and dehiscence, P = .37), or thirty‐day readmission (P = .3).Conclusion: Following free flap reconstruction, patient age did not correlate with development of a surgical complication. Patient age did correlate with development of a medical complication. Postoperative medical complications were found to correlate with perioperative mortality.Level of Evidence: 4 Laryngoscope, 132:772–780, 2022


  • Open Access

    Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss

    by Meiyan Jiang, Hongzhe Li, Anastasiya Johnson, Takatoshi Karasawa, Yuan Zhang, William B. Meier, Farshid Taghizadeh, Allan Kachelmeier, Peter S. Steyger

    Aminoglycoside antibiotics are essential for treating life-threatening bacterial infections, despite the risk of lifelong hearing loss. Infections induce inflammation and up-regulate expression of candidate aminoglycoside-permeant cation channels, including transient receptor potential vanilloid-1 (TRPV1). Heterologous expression of TRPV1 facilitated cellular uptake of (fluorescently tagged) gentamicin that was enhanced by agonists, and diminished by antagonists, of TRPV1. Cochlear TRPV1 was immunolocalized near the apical membranes of sensory hair cells, adjacent supporting cells, and marginal cells in the stria vascularis. Exposure to immunostimulatory lipopolysaccharides, to simulate of bacterial infections, increased cochlear expression of TRPV1 and hair cell uptake of gentamicin. Lipopolysaccharide exposure exacerbated aminoglycoside-induced auditory threshold shifts and loss of cochlear hair cells in wild-type, but not in heterozygous Trpv1+/− or Trpv1 knockout, mice. Thus, TRPV1 facilitates cochlear uptake of aminoglycosides, and bacteriogenic stimulation upregulates TRPV1 expression to exacerbate cochleotoxicity. Furthermore, loss-of-function polymorphisms in Trpv1 can protect against immunogenic exacerbation of aminoglycoside-induced cochleotoxicity.


  • Open Access

    Potential Mechanisms Underlying Inflammation-Enhanced Aminoglycoside-Induced Cochleotoxicity

    by Meiyan Jiang, Farshid Taghizadeh, Peter S. Steyger

    Aminoglycoside antibiotics remain widely used for urgent clinical treatment of life-threatening infections, despite the well-recognized risk of permanent hearing loss, i.e., cochleotoxicity. Recent studies show that aminoglycoside-induced cochleotoxicity is exacerbated by bacteriogenic-induced inflammation. This implies that those with severe bacterial infections (that induce systemic inflammation), and are treated with bactericidal aminoglycosides are at greater risk of drug-induced hearing loss than previously recognized. Incorporating this novel comorbid factor into cochleotoxicity risk prediction models will better predict which individuals are more predisposed to drug-induced hearing loss. Here, we review the cellular and/or signaling mechanisms by which host-mediated inflammatory responses to infection could enhance the trafficking of systemically administered aminoglycosides into the cochlea to enhance the degree of cochleotoxicity over that in healthy preclinical models. Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of drug-induced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides.